CureVac N.V.

News & Events

Press Releases

In The Media

1. CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

   ACCESS Newswire APR 10, 2025 7:30 AM EDT
   Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate T...
   READ ARTICLE

2. CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

   ACCESS Newswire APR 8, 2025 7:25 AM EDT
   TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), ...
   READ ARTICLE

3. CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

   ACCESS Newswire APR 7, 2025 7:15 AM EDT
   Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investi...
   READ ARTICLE

4. CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

   ACCESS Newswire MAR 27, 2025 4:30 PM EDT
   European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challengin...
   READ ARTICLE

5. CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

   ACCESS Newswire FEB 18, 2025 7:15 AM EST
   CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgm...
   READ ARTICLE

6. CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

   ACCESS Newswire NOV 12, 2024 7:20 AM EST
   Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter &...
   READ ARTICLE

7. CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

   ACCESS Newswire NOV 7, 2024 7:30 AM EST
   TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVA...
   READ ARTICLE

8. CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

   ACCESS Newswire NOV 4, 2024 7:20 AM EST
   Experienced CFO and investment banker with 30-year track record will help drive CureVac's transfo...
   READ ARTICLE

9. CureVac to Present at the 12th International mRNA Health Conference

   ACCESS Newswire NOV 4, 2024 7:15 AM EST
   TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVA...
   READ ARTICLE

10. CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

    ACCESS Newswire OCT 28, 2024 8:10 AM EDT
    TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVA...
    READ ARTICLE